(Q88098767)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

review article

1 reference

title

Polycystic ovary syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

polycystic ovary syndrome

20 March 2020

main subject

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Richard S. Legro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Daria Lizneva

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Bulent O Yildiz

10

1 reference

ORCID Public Data File 2021

Enrico Carmina

2

object named as

Enrico Carmina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ricardo Azziz

1

0 references

author name string

Andrea Dunaif

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Joop S E Laven

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Barbara Natterson-Horowtiz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Helena J Teede

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

11 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Disease Primers

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

16057

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Heritability of polycystic ovary syndrome in a Dutch twin-family study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin resistance and polycystic ovary syndrome through life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Criteria, prevalence, and phenotypes of polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The prevalence of androgen excess among patients with minimal unwanted hair growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome--a long term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Referral bias in female functional hyperandrogenism and polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Of PCOS symptoms, hirsutism has the most significant impact on the quality of life of Iranian women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Reproductive health of women electing bariatric surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Impact of obesity on the risk for polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Association between fat mass- and obesity-associated (FTO) gene polymorphism and polycystic ovary syndrome: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

BMI-associated alleles do not constitute risk alleles for polycystic ovary syndrome independently of BMI: a case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Relationship between Polycystic Ovarian Syndrome and Subsequent Gestational Diabetes Mellitus: A Nationwide Population-Based Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Pregnancy complications in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome: metabolic consequences and long-term management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Risk of coronary heart disease and risk of stroke in women with polycystic ovary syndrome: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

A 20-year follow-up of young women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

31 March 2020

Cancer risk and PCOS.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The development of the polycystic ovary syndrome: family history as a risk factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Genetics of the polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Family-based analysis of INSR polymorphisms in Chinese PCOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Family-based analysis of eight susceptibility loci in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

PCOS in 2015: New insights into the genetics of polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome susceptibility single nucleotide polymorphisms in women with a single PCOS clinical feature.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Pathway Analysis Based on a Genome-Wide Association Study of Polycystic Ovary Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Hyperandrogenaemia in adolescent girls: origins of abnormal gonadotropin-releasing hormone secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Anti-Müllerian hormone and ovarian dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Anti-müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Dynamics of bioactive follicle-stimulating hormone secretion in women with polycystic ovary syndrome: effects of estradiol and progesterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Formation and early development of follicles in the polycystic ovary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin and C-peptide levels in obese patients with polycystic ovaries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin and C-peptide secretion in non-obese patients with polycystic ovarian disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin resistance in polycystic ovary syndrome is associated with defective regulation of ERK1/2 by insulin in skeletal muscle in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Insulin resistance is not conserved in myotubes established from women with PCOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Adipose Tissue Has Aberrant Morphology and Function in PCOS: Enlarged Adipocytes and Low Serum Adiponectin, But Not Circulating Sex Steroids, Are Strongly Associated with Insulin Resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

MicroRNA-223 Expression is Upregulated in Insulin Resistant Human Adipose Tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Functional genomics of PCOS: from GWAS to molecular mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The adrenal and polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome: a biopsychosocial understanding in young women to improve knowledge and treatment options

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Women's experiences of polycystic ovary syndrome diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

'The thief of womanhood': women's experience of polycystic ovarian syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Sleep disturbances in a community-based sample of women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Dietary Composition in the Treatment of Polycystic Ovary Syndrome: A Systematic Review to Inform Evidence-Based Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Effects of exercise and group counselling on body composition and VO2max in overweight women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Exercise therapy in polycystic ovary syndrome: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Reflections on inositol(s) for PCOS therapy: steps toward success

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Effects of acarbose on polycystic ovary syndrome: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Effect of vitamin D on clinical and biochemical parameters in polycystic ovary syndrome women: A meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Approach to the patient: contraception in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Three decades after Gjönnaess's laparoscopic ovarian drilling for treatment of PCOS; what do we know? An evidence-based approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

A systematic review of commonly used medical treatments for hirsutism in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Assessment, diagnosis and treatment of a patient with hirsutism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Relative safety and efficacy of finasteride for treatment of hirsutism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Androgen excess: Investigations and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Letrozole versus clomiphene for infertility in the polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Consensus on infertility treatment related to polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Is ovarian reserve diminished after laparoscopic ovarian drilling?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Long-term outcomes in women with polycystic ovary syndrome initially randomized to receive laparoscopic electrocautery of the ovaries or ovulation induction with gonadotrophins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

In Vitro Maturation in Women with vs. without Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Live birth after fresh embryo transfer vs elective embryo cryopreservation/frozen embryo transfer in women with polycystic ovary syndrome undergoing IVF (FreFro-PCOS): study protocol for a multicenter, prospective, randomized controlled clinical tri

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The use of metformin for women with PCOS undergoing IVF treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Health status assessment methods for adults: past accomplishments and future challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Quality of life and psychological well being in polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Determinants of emotional distress in women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Metabolic profile in sons of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovary syndrome: an ancient disorder?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Early metabolic derangements in daughters of women with polycystic ovary syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovaries in childhood: a common finding in daughters of PCOS patients. A pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Endocrine consequences of premature pubarche in post-pubertal Caucasian girls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Prospective follow-up of menstrual disorders in adolescence and prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Polycystic ovaries in nonobese adolescents and young women with ovarian androgen excess: relation to prenatal growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Fetal growth, length of gestation, and polycystic ovaries in adult life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

Pathogenesis of NIDDM. A balanced overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.57

31 March 2020

Identifiers

DOI

10.1038/NRDP.2016.57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27510637%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference